In my view, that's a clear example of the perverse incentives PBMs have created that leave so many Americans fed up and outraged at the health-care system in this country.

It undermines the negotiation entirely.

I am working on a bill with Senator Grassley, the Pharmacy Benefit Manager Transparency Act, which would shine a light on bad PBM practices.

It undermines the negotiation entirely.

The Pharmacy Benefit Manager Transparency Act of 2023 would make material improvements to the transparency of the U.S. health-care system.

The problem is that the person negotiating on behalf of the patient should not be getting paid by the other side.

I am working on a bill with Senator Grassley, the Pharmacy Benefit Manager Transparency Act, which would shine a light on bad PBM practices.

The Pharmacy Benefit Manager Transparency Act of 2023 would make material improvements to the transparency of the U.S. health-care system.

Every drug should have a price that is available for all to see and creates equity.

I'm proud to say that this is a hearing with strong bipartisan interest, and Senator Crapo and I have agreed to take on this issue together.

Your bill with Senator Grassley should make it more difficult for PBMs to hide profits from regulators.

I am going to go out and have all these town hall meetings, and I am going to hold that up.

Taxpayers, seniors facing a 2,000-percent markup.

People care a whole lot about this matter of getting mugged at the pharmacy counter.

We want to make this a bipartisan effort in this committee.

What recommendations do you have for how and where to increase transparency throughout the prescription drug supply chain?

The average price that PBMs charge Medicare Part D plans for the exact same drug is over $3,000.

this is more reason for the Congress and this Committee to step in and do this job and do it in a bipartisan way.